Though EPZ-5676 shows high efficacy when used in monotherapy against mixed lineage leukemias bearing MLL rearrangements, its therapeutic efficacy is further augmented by using this inhibitor with other standard of care agents for acute leukemias [61]. The gene discussed is KMT2A; the disease is leukemia.